This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Articles in this important issue include: Epidemiology of Follicular Lymphoma, Pathogenesis of Follicular Lymphoma, Circulating tumor DNA and MRD assessment in Follicular Lymphoma, Clinical and biological prognostic factors in Follicular Lymphoma, Vitamin D and Follicular Lymphoma, Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma, Initial Treatment of High Tumor Burden Follicular Lymphoma, Maintenance Antibody Therapy of Follicular Lymphoma, Cellular Therapy in Follicular Lymphoma, Immunomodulatory Agents in Follicular Lymphoma, Phosphoinositide 3-Kinase Inhibition in Follicular Lymphoma, Novel Agents Beyond Immunomodulatory Imide Drugs and Phosphoinositide 3-Kinases for Follicular Lymphoma, Early progression of Follicular Lymphoma, Biological Basis of Histological Transformation, and Treatment of Histological Transformation.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin’s Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin’s Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin’s lymphoma; and Targeting biology in non-Hodgkin’s lymphoma.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Articles in this important issue include: Epidemiology of Follicular Lymphoma, Pathogenesis of Follicular Lymphoma, Circulating tumor DNA and MRD assessment in Follicular Lymphoma, Clinical and biological prognostic factors in Follicular Lymphoma, Vitamin D and Follicular Lymphoma, Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma, Initial Treatment of High Tumor Burden Follicular Lymphoma, Maintenance Antibody Therapy of Follicular Lymphoma, Cellular Therapy in Follicular Lymphoma, Immunomodulatory Agents in Follicular Lymphoma, Phosphoinositide 3-Kinase Inhibition in Follicular Lymphoma, Novel Agents Beyond Immunomodulatory Imide Drugs and Phosphoinositide 3-Kinases for Follicular Lymphoma, Early progression of Follicular Lymphoma, Biological Basis of Histological Transformation, and Treatment of Histological Transformation.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

This issue of Hematology/Oncology Clinics of North America, guest edited by Drs. Bipin Savani and Mohamad Mohty, is devoted to Bone Marrow Transplantation. Articles in this issue include: Acute Myeloid Leukemia (AML); Acute Lymphoid Leukemia (ALL); Myelodysplastic Syndrome (AML); Myeloproliferative disorders (MPD); Chronic Lymphoid Leukemia; Chronic Myeloid Leukemia (CML); Multiple Myeloma and Amyloidosis; Non-Hodgkin Lymphoma (NHL); Hodgkin Lymphoma (HL); Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH); Sickle Cell Anemia; Thalassemia; Benign immunodeficiency diseases; and Referral to transplant centers.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.

This issue will focus on the global state of hematology and will include articles such as: The Global Burden of Anemia, Iron Deficiency Anemia: Problems in Diagnosis and Therapy, Progress Towards the Control and Management of the Thalassemias, Problems and Approaches for Blood Transfusion in the Developing Countries, and many more!

In this issue of Hematology/Oncology Clinics, guest editor Dr. David E. Fisher brings his considerable expertise to the topic of Cutaneous Oncology. Top experts first provide information on skin structure, function, and immunology, then offer overviews of the therapeutic state of the art for both melanoma and non-melanoma skin cancers. Discussions focus on unique clinical challenges and biological breakthroughs which have come to light in recent studies of cutaneous malignancies. - Contains 16 relevant, practice-oriented topics including high risk non-melanoma skin cancers; progress in immune checkpoints for melanoma therapy; targeted therapy innovations for melanoma; advances in vaccines for melanoma; microbiome and immunotherapy; Merkel cell carcinoma; and more. - Provides in-depth clinical reviews on cutaneous oncology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Raymond L. Comenzo, is devoted to Systemic Amyloidosis due to Monoclonal Immunoglobulins. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: The Spectrum of Monoclonal Immunoglobulin Diseases, Systemic Amyloidosis due to Clonal Plasma Cell Diseases, Systemic Amyloidosis due to Low-grade Lymphomas, The Process of Amyloid Formation due to Monoclonal Immunoglobulins, Cardiac Involvement, Renal Involvement, Liver and Gastrointestinal Involvement, Peripheral Nervous System Involvement, Options for Chemotherapy, Stem-cell Mobilization and Autologous Transplant, Monoclonal Antibody Therapies, Solid Organ Transplant, Supportive Care, Patient Voices, and Future Perspectives.